Alexion Pharmaceuticals - ALXN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$182.50
+0 (0.00%)
Get New Alexion Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALXN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALXN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Alexion Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $182.50.

This chart shows the closing price for ALXN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Alexion Pharmaceuticals. This rating has held steady since May 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 5 buy ratings
  • 15 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 14 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 12 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/5/2021OppenheimerUpgradeMarket Perform ➝ Outperform$205.00Low
5/3/2021SVB LeerinkBoost TargetMarket Perform$156.00 ➝ $173.00Medium
4/26/2021Credit Suisse GroupInitiated CoverageNeutral$190.00Low
3/29/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$196.00 ➝ $156.00N/A
3/23/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$196.00 ➝ $156.00Medium
2/5/2021SVB LeerinkLower TargetOutperform$200.00 ➝ $196.00Medium
2/4/2021Piper SandlerDowngradeOverweight ➝ NeutralLow
1/8/2021Raymond JamesDowngradeOutperform ➝ Market PerformLow
12/16/2020Truist FinancialDowngradeBuy ➝ Hold$155.00 ➝ $175.00Medium
12/15/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$175.00Low
12/15/2020Roth CapitalBoost Target$50.00 ➝ $73.00Low
12/14/2020SVB LeerinkBoost TargetOutperform$159.00 ➝ $200.00High
12/14/2020Robert W. BairdDowngradeOutperform ➝ Neutral$140.00 ➝ $175.00High
12/14/2020WedbushDowngradeOutperform ➝ Neutral$175.00High
12/14/2020Royal Bank of CanadaBoost TargetOutperform$139.00 ➝ $175.00High
12/14/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$152.00 ➝ $175.00High
12/14/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$147.00 ➝ $194.00High
11/19/2020Sanford C. BernsteinInitiated CoverageMarket Perform$148.00Low
11/5/2020Smith Barney CitigroupBoost Target$145.00 ➝ $157.00Low
11/5/2020Royal Bank of CanadaReiterated RatingBuyMedium
10/30/2020SVB LeerinkBoost TargetOutperform$159.00 ➝ $163.00Medium
10/30/2020Morgan StanleyLower TargetEqual Weight$121.00 ➝ $119.00Medium
10/29/2020Piper SandlerBoost TargetOverweight$175.00 ➝ $179.00Medium
10/28/2020UBS GroupInitiated CoverageNeutral$133.00High
10/13/2020Morgan StanleyBoost TargetEqual Weight$120.00 ➝ $121.00Low
10/7/2020Royal Bank of CanadaBoost TargetOutperform$136.00 ➝ $139.00High
10/7/2020William BlairReiterated RatingHoldHigh
10/6/2020WedbushReiterated RatingOutperform$156.00Low
9/1/2020Stifel NicolausLower TargetHold$120.00 ➝ $117.00Low
7/31/2020Raymond JamesLower TargetOutperform$156.00 ➝ $151.00Low
7/31/2020SunTrust BanksBoost TargetOutperform ➝ Buy$135.00 ➝ $155.00Medium
7/31/2020SVB LeerinkBoost TargetOutperform$159.00 ➝ $163.00Medium
7/30/2020William BlairDowngradeOutperform ➝ Market PerformHigh
7/30/2020OppenheimerReiterated RatingHoldMedium
6/1/2020WedbushBoost TargetOutperform$120.00 ➝ $138.00Low
6/1/2020Credit Suisse GroupBoost TargetOutperform$142.00 ➝ $147.00Low
5/29/2020SVB LeerinkBoost TargetOutperform$150.00 ➝ $159.00High
5/26/2020Credit Suisse GroupInitiated CoverageBuy$142.00High
5/8/2020SunTrust BanksLower TargetBuy$141.00 ➝ $135.00Low
5/7/2020BMO Capital MarketsLower TargetOutperform$147.00 ➝ $142.00Low
5/7/2020SVB LeerinkLower TargetOutperform$156.00 ➝ $150.00Low
5/7/2020Raymond JamesLower TargetOutperform$159.00 ➝ $156.00Low
5/7/2020Morgan StanleyBoost TargetEqual Weight$116.00 ➝ $120.00Low
5/6/2020CfraLower TargetStrong-Buy$165.00 ➝ $159.00Medium
5/6/2020NomuraReiterated RatingBuy$133.00Medium
5/5/2020William BlairDowngradeOutperform ➝ Market PerformMedium
4/27/2020Cantor FitzgeraldInitiated CoverageNeutral$121.00High
4/20/2020UBS GroupReiterated RatingReduceHigh
4/17/2020JPMorgan Chase & Co.Lower TargetOverweight$168.00 ➝ $163.00High
4/15/2020Morgan StanleyLower TargetEqual Weight$127.00 ➝ $116.00Low
3/17/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
3/12/2020Wolfe ResearchInitiated CoverageOutperform$140.00High
3/5/2020Bank of AmericaDowngradeBuy ➝ Neutral$130.00 ➝ $110.00Low
2/25/2020SunTrust BanksReiterated RatingBuy$141.00Medium
2/3/2020Nomura SecuritiesLower TargetBuy$165.00 ➝ $133.00Low
1/31/2020Robert W. BairdLower TargetOutperform$165.00 ➝ $140.00High
1/31/2020Royal Bank of CanadaInitiated CoverageOutperform ➝ Positive$135.00Medium
1/31/2020Raymond JamesLower TargetOutperform$162.00 ➝ $159.00Medium
1/31/2020SunTrust BanksBoost TargetBuy$141.00High
1/30/2020CowenReiterated RatingBuy$165.00High
1/19/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
1/17/2020Morgan StanleyBoost TargetEqual Weight$128.00 ➝ $131.00Low
1/15/2020Raymond JamesBoost TargetOutperform$162.00Low
1/14/2020William BlairReiterated RatingBuyMedium
1/13/2020WedbushReiterated RatingOutperformHigh
12/17/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$170.00 ➝ $128.00Low
12/6/2019William BlairReiterated RatingBuyLow
11/17/2019Evercore ISIReiterated RatingBuy$145.00Low
11/12/2019SunTrust BanksInitiated CoverageBuy$125.00Low
10/24/2019OppenheimerLower Target$165.00 ➝ $150.00Low
10/17/2019Bank of AmericaInitiated CoverageBuyLow
10/16/2019CowenReiterated RatingBuy$165.00Low
10/11/2019Morgan StanleyLower TargetOverweight$177.00 ➝ $170.00Low
9/26/2019William BlairInitiated CoverageOutperform ➝ Outperform$146.00High
9/18/2019Royal Bank of CanadaReiterated RatingBuyLow
9/12/2019BMO Capital MarketsInitiated CoverageOutperform$149.00Low
9/6/2019Piper Jaffray CompaniesSet TargetBuy$180.00Low
9/6/2019Credit Suisse GroupLower TargetOutperform$154.00 ➝ $146.00High
9/3/2019SVB LeerinkSet TargetBuy$157.00Low
8/30/2019Piper Jaffray CompaniesSet TargetBuy$180.00Low
8/30/2019CitigroupSet TargetBuy$150.00Low
8/30/2019Stifel NicolausReiterated RatingHoldLow
8/30/2019Raymond JamesSet TargetBuy$168.00Low
8/30/2019Robert W. BairdSet TargetBuy$165.00Low
8/22/2019Piper Jaffray CompaniesReiterated RatingBuyLow
8/21/2019Morgan StanleySet TargetBuy$177.00N/A
7/31/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$172.00Low
7/25/2019Raymond JamesBoost TargetOutperform$164.00 ➝ $168.00High
5/23/2019CitigroupLower TargetBuy ➝ Buy$180.00 ➝ $165.00Low
5/23/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$142.00Low
5/22/2019WedbushInitiated CoverageOutperform ➝ Outperform$173.00Medium
4/26/2019Raymond JamesBoost TargetOutperform ➝ Outperform$161.00 ➝ $164.00Low
4/10/2019Raymond JamesInitiated CoverageOutperform$161.00Medium
3/27/2019Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$165.00 ➝ $186.00Low
3/21/2019GuggenheimReiterated RatingNeutral ➝ Neutral$135.00High
3/13/2019CowenReiterated RatingBuy$165.00Low
2/22/2019GuggenheimInitiated CoverageNeutral ➝ Neutral$135.00Medium
2/12/2019Morgan StanleyBoost TargetOverweight ➝ Overweight$165.00 ➝ $175.00High
1/22/2019Credit Suisse GroupReiterated RatingBuy$156.00Medium
12/30/2018Raymond JamesReiterated RatingBuyLow
12/30/2018Credit Suisse GroupSet TargetBuy$156.00Low
12/21/2018Credit Suisse GroupReiterated RatingBuy$156.00Low
12/21/2018Raymond JamesReiterated RatingBuyHigh
11/26/2018OppenheimerSet TargetBuy$165.00Medium
11/14/2018OppenheimerSet TargetBuy$165.00Medium
11/13/2018Credit Suisse GroupSet TargetBuy$156.00Medium
10/31/2018Credit Suisse GroupSet TargetBuy$156.00High
10/25/2018CitigroupLower TargetBuy$195.00 ➝ $190.00Medium
10/24/2018SVB LeerinkSet TargetBuy$181.00High
10/15/2018Credit Suisse GroupSet TargetBuy$156.00High
10/11/2018Morgan StanleyBoost TargetOverweight$157.00 ➝ $165.00Low
9/28/2018BarclaysBoost TargetPositive ➝ Overweight$175.00Low
9/25/2018Credit Suisse GroupSet TargetBuy$156.00Low
9/25/2018Stifel NicolausBoost TargetHold ➝ Hold$130.00 ➝ $136.00Low
9/25/2018CitigroupBoost TargetBuy ➝ Buy$173.00 ➝ $195.00Low
9/24/2018Robert W. BairdSet TargetBuy$165.00Medium
8/7/2018Stifel NicolausDowngradeBuy ➝ Hold$154.00 ➝ $130.00Low
7/27/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$150.00 ➝ $157.00High
7/27/2018JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$184.00 ➝ $188.00High
7/27/2018Jefferies Financial GroupReiterated RatingHold$123.00High
7/26/2018Evercore ISIReiterated RatingOutperform$158.00Medium
6/5/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$149.00 ➝ $154.00Low
4/30/2018CitigroupBoost TargetBuy ➝ Buy$170.00 ➝ $173.00Medium
4/27/2018Credit Suisse GroupSet TargetBuy$149.00Medium
4/27/2018Stifel NicolausBoost TargetBuy ➝ Buy$151.00 ➝ $155.00Low
4/23/2018Raymond JamesReiterated RatingBuyLow
4/12/2018Nomura SecuritiesBoost TargetBuy$165.00Low
3/16/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$147.00 ➝ $149.00High
3/15/2018Nomura SecuritiesBoost TargetBuy ➝ Buy$148.00 ➝ $156.00Low
3/15/2018Robert W. BairdSet TargetBuy$160.00Low
3/15/2018Deutsche Bank AktiengesellschaftSet TargetBuy$161.00High
3/9/2018CowenReiterated RatingBuy$163.00Low
2/12/2018SunTrust BanksSet TargetBuy$172.00Medium
2/9/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$177.00 ➝ $180.00Low
2/9/2018Stifel NicolausReiterated RatingBuy$151.00Medium
2/9/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$148.00 ➝ $151.00Low
2/9/2018SVB LeerinkLower TargetOutperform ➝ Outperform$166.00 ➝ $153.00Low
2/9/2018Deutsche Bank AktiengesellschaftSet TargetBuy ➝ Buy$163.00 ➝ $161.00Low
2/9/2018CitigroupLower TargetBuy ➝ Buy$173.00 ➝ $170.00Low
2/5/2018Evercore ISIUpgradeIn-Line ➝ OutperformHigh
1/18/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$147.00Medium
1/4/2018Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$178.00 ➝ $130.00Medium
1/4/2018UBS GroupDowngradeStrong-Buy ➝ OutperformMedium
12/18/2017Robert W. BairdUpgradeNeutral ➝ Outperform$150.00Medium
12/12/2017Credit Suisse GroupReiterated RatingBuy$166.00Low
12/6/2017SVB LeerinkReiterated RatingBuy$169.00Low
10/24/2017Royal Bank of CanadaBoost Target$166.00N/A
10/24/2017Stifel NicolausLower TargetBuy$165.00 ➝ $159.00N/A
10/23/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$170.00N/A
(Data available from 10/3/2017 forward)

News Sentiment Rating

-0.64 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/4/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/3/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Alexion Pharmaceuticals logo
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $182.50
Low: $182.50
High: $182.50

50 Day Range

MA: $182.82
Low: $179.45
High: $186.61

52 Week Range

Now: $182.50
Low: $99.91
High: $187.45

Volume

10 shs

Average Volume

3,309,941 shs

Market Capitalization

$40.34 billion

P/E Ratio

59.64

Dividend Yield

N/A

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Alexion Pharmaceuticals?

The following Wall Street research analysts have issued reports on Alexion Pharmaceuticals in the last twelve months:
View the latest analyst ratings for ALXN.

What is the current price target for Alexion Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Alexion Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Alexion Pharmaceuticals in the next year.
View the latest price targets for ALXN.

What is the current consensus analyst rating for Alexion Pharmaceuticals?

Alexion Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ALXN.

What other companies compete with Alexion Pharmaceuticals?

How do I contact Alexion Pharmaceuticals' investor relations team?

Alexion Pharmaceuticals' physical mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company's listed phone number is 475-230-2596 and its investor relations email address is [email protected] The official website for Alexion Pharmaceuticals is www.alexion.com. Learn More about contacing Alexion Pharmaceuticals investor relations.